On July 31st, 2025, the U.S. Food and Drug Administration announced sweeping changes to the safety labeling of all opioid pain medications. These updates aim to better communicate the risks of long-term opioid use—risks that include misuse, addiction, overdose, and a range of serious side effects.

For drug manufacturers, this means updating product labels to help patients, doctors, pharmacists, and other healthcare providers make more informed decisions. But the implications go far beyond packaging—they touch on the very science of how opioids interact with the human body.

Read the full article

• FDA Requires Drug Manufacturers to Update Prescribing Information for Opioid Pain Medicines

About the author

• L. Christine Lawson